We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
However, the impact of diabetes on survival in patients treated with fibrinolyticagents is still undefined.
2
Attempts to improve thrombolytic treatment include the search for better fibrinolyticagents and more effective adjunctive therapies.
3
The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolyticagents.
4
Conclusions: A history of diabetes is associated with a worse prognosis after myocardial infarction, even in patients treated with fibrinolyticagents.
5
Methods: We analyzed prevalence and prognostic significance of a history of diabetes in patients enrolled in the GISSI-2 study, all of whom received fibrinolyticagents.
1
Current methods for enzymatic activity of thrombolyticdrugs are costly and complex.
2
Its efficacy is comparable to that of other available thrombolyticdrugs.
3
Early treatment with thrombolyticdrugs has been shown to reduce mortality in patients with acute myocardial infarction.
4
Thrombolyticdrugs (rt-PA followed by Streptokinase) were injected via the same filter catheter.
1
These findings indicated that AnxB1ScuPA might have advantages over current available thrombolyticagents.
2
However, thrombolyticagents have limited effectiveness and are associated with a significant risk of bleeding.
3
The newer-generation thrombolyticagents remain of limited efficacy in the treatment and prevention of shock.
4
Twelve randomized, controlled trials of thrombolyticagents in 611 UA patients with predefined clinical endpoints have been published.
5
This meta-analysis showed that thrombolyticagents significantly improved the rate of return of spontaneous circulation, 24 h surviva …
1
However, the impact of diabetes on survival in patients treated with fibrinolyticagents is still undefined.
2
Attempts to improve thrombolytic treatment include the search for better fibrinolyticagents and more effective adjunctive therapies.
3
The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolyticagents.
4
Conclusions: A history of diabetes is associated with a worse prognosis after myocardial infarction, even in patients treated with fibrinolyticagents.
5
Methods: We analyzed prevalence and prognostic significance of a history of diabetes in patients enrolled in the GISSI-2 study, all of whom received fibrinolyticagents.